SAN DIEGO, June 15, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader in precision healthcare, announces the execution of an agreement with MultiPlan, a trusted partner to ...
Respondr (R) TNF Indicates Likelihood of Patient Response to Costly IBD Treatment Before Initiation of Therapy SAN DIEGO, CA / ACCESS Newswire / April 29, 2025 / Prometheus Laboratories Inc.
SAN DIEGO, CA / ACCESS Newswire / December 8, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, announces the launch of IBD Precis ™, a next-generation ...
SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...
PredictrPK® IFX influenced changes in care in 58% of cases and confirmed current treatment approach in the remaining 42% SAN DIEGO, CA / ACCESSWIRE / December 21, 2023 / Prometheus Laboratories Inc. ( ...
NEW YORK, Nov 7 (Reuters) - Privately held Prometheus Laboratories Inc said on Wednesday it has agreed to acquire exclusive U.S. rights to GlaxoSmithKline's irritable bowel syndrome drug Lotronex.
The MarketWatch News Department was not involved in the creation of this content. New Therapeutic Drug Monitoring Test for Interleukin--23 Inhibitor SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / ...
Article ‘Count’ and ‘Share’ for Prometheus Laboratories Inc. based on listed parameters only. According to the parameters selected above, there are no articles from Prometheus Laboratories Inc. from 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback